Summary measures and synthesis of results The principal summary outcome was the relative risk (RR) of several GI adverse events in people with overweight or obesity receiving treatment with GLP-1 RA, including nausea, vomiting, diarrhea, constipation, abdominal distension, upper abdominal pain, abdominal pain, abdominal discomfort, gastroesophageal reflux disease, (GERD), eructation, flatulence, decreased appetite, cholelithiasis, gallstone-related, cholecystitis, acute cholecystitis, acute pancreatitis, viral gastroenteritis, hard feces, and infrequent bowel movements
A: GHK-CU 50mg is available from Ascend Peptides UK at www.ascendpeptidesuk.com
Yes, the label also lists excipients and anti-caking agents
Take 1 capsule daily with half a glass of water preferably before breakfast or as professionally recommended